Athanor Capital’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Athanor Capital’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,477	Closed	-$1.38M	–	1129
2020 Q4	$1.38M	Buy	10,477 +1,147	+12%	+$101K	0.03%	246
2020 Q3	$471K	Sell	9,330 -6,122	-40%	-$275K	0.02%	349
2020 Q2	$737K	Buy	+15,452	New	+$719K	0.04%	242
2020 Q1	–	Sell	-10,741	Closed	-$616K	–	417
2019 Q4	$616K	Buy	10,741 +841	+8%	+$41.6K	0.03%	227
2019 Q3	$356K	Buy	+9,900	New	+$387K	0.02%	176

Athanor Capital's EIDX Position: Q1 2021 in Review

Athanor Capital sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 10,477 shares — an estimated $1.38M sold.

Athanor Capital first reported a position in EIDX in Q3 2019 and held it in 5 quarters. The position peaked at $1.38M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Athanor Capital reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 10,477 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.38M.
Athanor Capital first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
Athanor Capital's Eidos Therapeutics, Inc. Common Stock position peaked at $1.38M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.